Growth in the healthcare industry requires thorough research, innovative thinking, and visionary leadership. A healthcare researcher and leader should commit to the well-being of the patient and should adapt to technological changes. Dr. Mehmet Ali Soylemez, Founder & Managing Director of Soylemez Investment, is one such leader who has made significant changes in the healthcare sector with his dedicated research and groundbreaking innovations. He aims to make a difference by empowering healthcare professionals in their clinical decision-making, ultimately leading to improved patient care and reduced healthcare costs.
The Inspirational Work & Journey
Dr. Mehmet Ali Soylemez completed his studies at the Istanbul University, School of Medicine. Apart from being an entrepreneur, he is a distinguished medical doctor and scientist, with expertise in clinical genetics, general surgery, and medical physiology. He is a member of several scientific associations – the Turkish Medical Genetics Association, the American Society of Cell and Gene Therapy, the European Society of Human Genetics, and the American Society of Human Genetics. He has won several awards throughout his career, some of which are,
- European Society of Human Genetics; Fellowship Award, 2011, Amsterdam, Netherlands.
- GHP – Global Healthcare and Pharmaceutical Award Winner in 2023, Staffordshire, UK.
- CIO Bulletin Innovation Excellence Award Winner in 2024, New Jersey – USA.
- The Silicon Review 30 Fabulous Companies 2024 Award
- 30 Fabulous Invention Award Winner in 2024, New Jersey – USA.
Dr Mehmet Ali Soylemez’s immense knowledge and research have significantly influenced the healthcare industry, especially in diagnosing and managing diabetes mellitus and diabetic foot syndrome. One of his notable achievements is the identification of biomarker procalcitonin. His passion for collaboration and improving diabetic treatments has helped Soylemez Investment gain recognition.
Advancing the Healthcare Industry
Mehmet Ali Soylemez Investment, established by Dr. Mehmet Ali Söylemez, is at the forefront of technological innovation, aiming to advance multiple industries. Recognized for its ingenious contributions, particularly in advancing diabetic treatments, the company has earned accolades such as the Innovation Excellence Awards. With a commitment to constant improvement, the company dedicates itself to pushing the boundaries of what’s possible–leaving a lasting impact on healthcare and beyond. It is driven by ethical principles, with a focus on respecting human values and client needs. The company’s mission centers on advancing treatments for Diabetes Mellitus and Diabetic Foot Syndrome.
Söylemez Investment operates in a wide range of industries, from real estate to IP Investment. Dr Mehmet Ali Soylemez’s focus is on IP Investment within the company. He is open to working with biotech and diagnostic firms around the world that are after investment in accelerating their entry into the market. The company’s scientific goal is to design an individual diagnostic treatment plan to help every one of its diabetic patients achieve the best outcome possible.
The Diagnostic Biomarker Tool
The importance of designing individualized diagnostic treatment plans to optimize outcomes for diabetic patients is emphasized by Dr. Mehmet Ali Soylemez. His pioneering research has led to the widespread use of procalcitonin as a diagnostic biomarker for diabetes mellitus and diabetic foot syndrome. To safeguard his property, the company has submitted a patent application to the United States Patent and Trademark Office (USPTO) for two inventions related to diagnostic biomarkers. These patents aim to secure the company’s position in the US market and support its long-term strategic vision of growing with advancements in diagnostic and preventive healthcare.
Dr. Mehmet Ali Soylemez is the rightful owner of the European patent for this invention titled Pancreatic Diabetes in Patients with Normal Blood Leukocyte Counts Using Procalcitonin. It is registered with the European Patent Office. It is also protected by three national registries, including the United Kingdom, Sweden, and Turkey. These highlight the significance and uniqueness of his work. He envisions that the future of diagnostic and preventive healthcare advancements will rely on diagnostic biomarkers and molecular genetics. The company must be prepared to evolve to these market changes in the next five to ten years.
Changing the Healthcare Industry With the Invention
The identification of procalcitonin led to the revolutionization of the scientists’ understanding of these conditions and more effective treatment. The research has resulted in approximately 40 peer-reviewed publications on procalcitonin as a biomarker tool. It highlights its superiority over traditional diagnostics like HgbA1c.
HgbA1c shows three months of potential diabetic complications while procalcitonin shows a much smaller timeline – in the span of 24 hours – of potential damage from complications. It does this by identifying patients at risk of complications early on. So diabetic mellitus and diabetic complications can be treated faster and much more successfully.
Despite significant challenges, this development comes after two decades of hard work to raise awareness of the biomarker’s effectiveness in the market. The invention of procalcitonin has been submitted as a proposal for the Lasker Award 2024, Harvard Medical School’s Warren Alpert Prize 2024, and the European Inventor Award 2024.
